Lahey Medical Center Peabody 1 Essex Ctr Dr, Peabody, MA 01960 978 538-4000 (phone), 978 538-4712 (fax)
Lahey Health Outpatient General Surgery & Comprehensive Breast Health Center 41 Mall Rd, Burlington, MA 01805 781 744-8834 (phone), 781 744-5636 (fax)
Breast Health Center 480 Maple St, Danvers, MA 01923 978 304-8101 (phone), 978 304-8123 (fax)
Lahey Medical Center Peabody General Surgery & Breast Health Center 1 Essex Ctr Dr FL 3, Peabody, MA 01960 978 538-4250 (phone), 978 538-4720 (fax)
Education:
Medical School University of Maryland School of Medicine Graduated: 1993
Procedures:
Breast Biopsy Breast Reconstruction Mastectomy Thoracoscopy
Conditions:
Breast Disorders Malignant Neoplasm of Female Breast Benign Neoplasm of Breast Cholelethiasis or Cholecystitis Overweight and Obesity
Languages:
English
Description:
Dr. Yang graduated from the University of Maryland School of Medicine in 1993. She works in Danvers, MA and 4 other locations and specializes in General Surgery. Dr. Yang is affiliated with Beverly Hospital, Exeter Hospital, Lahey Hospital & Medical Center, Lahey Medical Center Peabody and Tufts Medical Center.
Berry Appleman & Leiden Llp
Senior Client Immigration Representative
Altair Global Feb 2015 - Apr 2018
Global Consultant
Baker Botts Jun 2014 - Jan 2015
Business Intake and Risk Management Analyst
Hogan Lovells 2013 - 2014
Conflicts Researcher
Diablo Valley College Feb 2011 - May 2011
Italian Tutor
Education:
American University 2013
Bachelors, Bachelor of Arts
American University 2011 - 2013
Bachelors, International Relations, International Studies
Contra Costa College 2009 - 2011
Diablo Valley College 2009 - 2011
Skills:
International Relations Italian Research Political Science English Spanish Intercultural Communication Microsoft Excel Microsoft Word Microsoft Office Public Speaking Social Media Foreign Languages Mandarin Shanghainese Powerpoint Economics European Union Laws and Policies World Politics Domestic/International Foreign and Security Policy Nato Corporate Research Foreign Government Research Lexis Nexis Elite Database Research Politics Policy Analysis Legal Research Foreign Policy Diplomacy Human Rights Spss Translation European Union Editing Qualitative Research Proofreading Legal Documents Multilingual Data Analysis International Security Legal Assistance Government Unbabel Italian Editor Localization Project Management
Interests:
Social Experimentation Psychology Animals and Exotic Pets Cultural Exchange Motorcycles Foreign Languages Diplomacy Travel Fishing
Microsoft Office Management Microsoft Excel Microsoft Word Research Powerpoint Sales Leadership Training Logistics Management Strategic Communications Corporate Communications
Emil D. Kakkis - Novato CA, US Merry Passage - Torrance CA, US Thomas Lester - Harbor City CA, US Rebecca Yang - Los Angeles CA, US Christopher Tanaka - Gardena CA, US
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA
International Classification:
A61K 45/00
US Classification:
4242781, 424 941
Abstract:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.
Induction Of Antigen Specific Immunnologic Tolerance
Emil D. Kakkis - Novato CA, US Thomas Lester - Harbor City CA, US Merry Passage - Torrance CA, US Christopher Tanaka - Gardena CA, US Rebecca Yang - Los Angeles CA, US
International Classification:
A61K 39/385
US Classification:
4241931, 4241981
Abstract:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.
Induction Of Antigen Specific Immunologic Tolerance
Emil Kakkis - Novato CA, US Thomas Lester - Harbor City CA, US Merry Passage - Torrance CA, US Christopher Tanaka - Gardena CA, US Rebecca Yang - Los Angeles CA, US
International Classification:
A61K038/13 A61K039/00
US Classification:
514/011000, 424/185100
Abstract:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.
Induction Of Antigen Specific Immunologic Tolerance
Emil Kakkis - Novato CA, US Thomas Lester - Cardiff CA, US Merry Passage - Torrance CA, US Christopher Tanaka - Gardena CA, US Rebecca Yang - Los Angeles CA, US
International Classification:
A61K039/00 A61K038/13 A61K031/7024 A61K031/522
US Classification:
424184100, 514011000, 514263310, 514023000
Abstract:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.